Literature DB >> 14683476

Akt in prostate cancer: possible role in androgen-independence.

Paramita M Ghosh1, Shazli Malik, Roble Bedolla, Jeffrey I Kreisberg.   

Abstract

Akt, a downstream effector of phosphatidylinositol 3-kinase (PI3K), has often been implicated in prostate cancer. Studies in prostate tumor cell lines revealed that Akt activation is probably important for the progression of prostate cancer to an androgen-independent state. Investigations of human prostate cancer tissues show that although there is neither Akt gene amplification nor enhanced protein expression in prostate cancer compared to normal tissue, poorly differentiated tumors exhibit increased expression of a phosphorylated (activated) form of Akt compared to normal tissue, prostatic intraepithelial neoplasia (PIN) or well-differentiated prostate cancer. Akt phosphorylation is accompanied by the inactivation of ERK, a member of the mitogen activated protein kinase (MAPK) family. In this article, we postulate that Akt promotes androgen-independent survival of prostate tumor cells by modulating the expression and activation of the androgen receptor (AR).

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14683476     DOI: 10.2174/1389200033489226

Source DB:  PubMed          Journal:  Curr Drug Metab        ISSN: 1389-2002            Impact factor:   3.731


  30 in total

1.  Understanding the stereospecific interactions of 3-deoxyphosphatidylinositol derivatives with the PTEN phosphatase domain.

Authors:  Qin Wang; Yang Wei; Madhusoodanan Mottamal; Mary F Roberts; Goran Krilov
Journal:  J Mol Graph Model       Date:  2010-05-20       Impact factor: 2.518

2.  Antagonists of growth hormone-releasing hormone inhibit growth of androgen-independent prostate cancer through inactivation of ERK and Akt kinases.

Authors:  Ferenc G Rick; Andrew V Schally; Luca Szalontay; Norman L Block; Karoly Szepeshazi; Mehrdad Nadji; Marta Zarandi; Florian Hohla; Stefan Buchholz; Stephan Seitz
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-18       Impact factor: 11.205

Review 3.  Targeted approaches for the management of metastatic prostate cancer.

Authors:  Kathleen W Beekman; Maha Hussain
Journal:  Curr Oncol Rep       Date:  2006-05       Impact factor: 5.075

4.  Quantitative in situ detection of phosphoproteins in fixed tissues using quantum dot technology.

Authors:  Juraj Bodo; Lisa Durkin; Eric D Hsi
Journal:  J Histochem Cytochem       Date:  2009-03-30       Impact factor: 2.479

5.  Epithelial phosphatidylinositol-3-kinase signaling is required for β-catenin activation and host defense against Citrobacter rodentium infection.

Authors:  Jeffrey B Brown; Paul Cheresh; Tatiana Goretsky; Elizabeth Managlia; Gery R Grimm; Hyunji Ryu; Mojgan Zadeh; Ramanarao Dirisina; Terrence A Barrett
Journal:  Infect Immun       Date:  2011-02-22       Impact factor: 3.441

Review 6.  Apoptosis evasion: the role of survival pathways in prostate cancer progression and therapeutic resistance.

Authors:  Shaun McKenzie; Natasha Kyprianou
Journal:  J Cell Biochem       Date:  2006-01-01       Impact factor: 4.429

7.  CXCL13 mediates prostate cancer cell proliferation through JNK signalling and invasion through ERK activation.

Authors:  C P El-Haibi; R Singh; P K Sharma; S Singh; J W Lillard
Journal:  Cell Prolif       Date:  2011-06-06       Impact factor: 6.831

8.  Antibody Microarray Analysis of Signaling Networks Regulated by Cxcl13 and Cxcr5 in Prostate Cancer.

Authors:  Christelle P El-Haibi; Rajesh Singh; Pranav Gupta; Praveen K Sharma; Krysta N Greenleaf; Shailesh Singh; James W Lillard
Journal:  J Proteomics Bioinform       Date:  2012

9.  Targeting ErbB3: the New RTK(id) on the Prostate Cancer Block.

Authors:  Maitreyee K Jathal; Liqun Chen; Maria Mudryj; Paramita M Ghosh
Journal:  Immunol Endocr Metab Agents Med Chem       Date:  2011-06

10.  Resveratrol regulates the PTEN/AKT pathway through androgen receptor-dependent and -independent mechanisms in prostate cancer cell lines.

Authors:  Yu Wang; Todd Romigh; Xin He; Mohammed S Orloff; Robert H Silverman; Warren D Heston; Charis Eng
Journal:  Hum Mol Genet       Date:  2010-08-20       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.